However, GLP-1 (9–36) AlbudAb (data not shown), didn’t significantly reduce myocardial infarct size in this study and it also had no effect on body weight and food intake following two days of treatment, suggesting activation of the GLP-1 receptor dependent pathway by GAlbudAb plays an important role in cardioprotection. Here, GLP1R is linked to myocardial infarction.